Wilson Ko, MD
Ophthalmology · Flushing, NYNPI 1770560096
Payments from drug & device makers
Across 313 payments — averaging $80.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$9K
- Sun Pharmaceutical Industries Inc.$8K
- Alcon$2K
- Dompe US, Inc.$1K
- Glaukos Corporation$1K
- Johnson & Johnson Surgical Vision, Inc.$604
- plus $3K from 24 others
What the payments were for
- Speaking & faculty fees$15,24561%
- Travel & lodging$370%
- Food & beverage$9,68439%
- Education$1000%
- Gifts$370%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 46 | $9,051 |
| Sun Pharmaceutical Industries Inc. | 41 | $8,447 |
| Alcon | 49 | $1,999 |
| Dompe US, Inc. | 35 | $1,171 |
| Glaukos Corporation | 13 | $1,013 |
| Johnson & Johnson Surgical Vision, Inc. | 11 | $604 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 18 | $350 |
| Oyster Point Pharma, Inc. | 16 | $325 |
| Tarsus Pharmaceuticals, Inc. | 10 | $320 |
| AbbVie(2 entities) | 15 | $301 |
| Amgen(2 entities) | 9 | $195 |
| Harrow Eye, LLC | 7 | $160 |
| Aerie Pharmaceuticals, Inc. | 3 | $157 |
| Eyevance Pharmaceuticals LLC | 7 | $145 |
| Novartis | 7 | $133 |
| Shire North American Group Inc | 6 | $106 |
| Rxsight Inc | 2 | $88 |
| NEW World Medical,inc. | 2 | $87 |
| Sight Sciences, Inc. | 1 | $79 |
| Thea Pharma Inc. | 3 | $68 |
| Coopervision Inc. | 2 | $65 |
| Covidien LP | 1 | $49 |
| Kala Pharmaceuticals, Inc. | 1 | $39 |
| Akorn Operating Company LLC | 2 | $39 |
| Astellas Pharma US Inc | 1 | $22 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Biotissue Holdings Inc. | 1 | $19 |
| Halozyme Inc | 1 | $19 |
| Carl Zeiss Meditec, Inc. | 1 | $17 |
| Ocular Therapeutix, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MIEBO$8,144
- XIIDRA$8,019
- CEQUA$7,736
- Oxervate$298
- Tecnis IOL$268
- ARGOS$243
- iStent infinite Trabecular Micro-Bypass System Model iS3$150
- iS3-iStent infiniteTrabecular Micro-Bypass System Model iS3$150
- TRYPTYR$150
- Clareon$150
- iStent inject Trabecular Micro-Bypass Stent System$142
- enVista MX60 IOL$140
- iDose$134
- AcrySof IQ VIVITY$134
- Rocklatan$125
- Rhopressa$125
- XDEMVY$115
- VERITAS Vision System$115
- CATALYS SYSTEM$115
How this compares
$25,104 in reported general payments places this provider in the 90th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 1,918 | $2,024,343 |
| OxervateCenegermin-Bkbj | 18 | $728,573 |
| ProlensaBromfenac Sodium | 1,017 | $354,219 |
| BesivanceBesifloxacin Hcl | 1,271 | $282,369 |
| XiidraLifitegrast | 220 | $271,565 |
| Prednisolone Acetate | 2,113 | $185,014 |
| Bepotastine Besilate | 634 | $120,825 |
| Cyclosporine | 208 | $112,080 |
| LumiganBimatoprost | 169 | $88,712 |
| CombiganBrimonidine Tartrate/Timolol | 125 | $57,670 |
| MieboPerfluorohexyloctane/Pf | 58 | $43,446 |
| Bromfenac Sodium | 196 | $37,296 |
| Alphagan PBrimonidine Tartrate | 70 | $25,618 |
| AlrexLoteprednol Etabonate | 59 | $25,415 |
| Loteprednol Etabonate | 167 | $23,317 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $301 | $2,196,3442,282 claims |
| Dompe US, Inc.Oxervate | $1,171 | $728,57318 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Besivance, Alrex, Loteprednol Etabonate, Bepreve | $350 | $711,4782,593 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta, Zirgan | $9,051 | $355,387369 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $8,447 | $22,48926 claims |
| NovartisIlevro | $133 | $14,43639 claims |
| Eyevance Pharmaceuticals LLCTobradex St | $145 | $11,35446 claims |
| Thea Pharma Inc.Iyuzeh | $68 | $10,66813 claims |
| Harrow Eye, LLCVevye | $160 | $10,53612 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $157 | $10,39034 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $325 | $9,89815 claims |
| AlconSimbrinza | $1,999 | $9,25333 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,587 ophthalmology providers in New York.
Other ophthalmology in Flushing
- Richard NajacFlushing$171K
- Douglas JabsNew York$24.3M
- David RubaltelliBrooklyn$8.9M
- Philip FerroneGreat Neck$5.8M
- Eric DonnenfeldGarden City$2.6M
- Nathan RadcliffeNew York$2.4M
- Glenn StollerRockville Centre$2.1M
- Richard SpaideNew York$1.7M
- Paul HartmanRochester$1.6M
- Jason SlakterNew York$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.